Kornimate/medical-research-clean huggingface dataset:
thoracoscopic exploration in comparison to exploratory thoracotomy in chest trauma

Conditions: Thoracic Injury

Summary: video-assisted thoracic surgery has a standard role in diagnosis and therapy in thoracic surgery, in the past, most patients necessitating surgical treatment secondary to chest trauma was exposed to open thoracotomy, which was the most morbid of surgical incisions

video-assisted thoracoscopic surgery has become a popular and acceptable method for diagnosis of intra-thoracic lesions since 1990s with the developments in surgical techniques. it is also used for treatment of retained pleural collections, it is a simple alternative to open thoracotomy. although it's multiple advantages, timing of surgery and its effects on patients' results are not well elucidated. multiple studies report that prognosis of patients is better with the earlier interventions in injured chest. however, there is so many differences for the optimal time for surgery in these studies . indications of vats have been extended for management of diagnosis and treatment of chest trauma since 1990. this approach has multiple advantages as chest tube setting, minimally invasive surgery, less postoperative pain, and chest exploration. today, vats is used for empyema, persistent pneumothorax, retained haemothorax, mediastinal and diaphragmatic exploration, pleuro-pericardial ruptures, surgery for thoracic duct injury and aspiration of symptomatic foreign bodies.

Eligibility criteria:
inclusion criteria: 1. patient aged more than 13 yards old 2. hemo-dynamically stable patients with chest trauma 3. willing and able to provide written informed consent and comply with study requirements. exclusion criteria: 1. patient aged less than 13 yards old. 2. hemo-dynamically instable patients 3. head trauma patients. 4. missing informed consent 5. participation in another clinical research.
retina is a marker for cerebrovascular heath

Conditions: Cerebral Small Vessel Diseases; Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy; Cerebral Microbleeding; Sporadic White Matter Disease

Summary: cerebral small vessel disease (svd), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. there is currently no treatment to slow svd progression. this study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for svd progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of svd.

this is a prospective, observational nested pilot randomized controlled study to discover retinal biomarkers that would predict cerebral small vessel disease progression, and evaluate the safety/efficacy of cilostazols in slowing svd progression. twenty cadasil, 40 swmd, 20 lobar cmb, and 20 age-matched healthy controls from the mayo clinic florida familial cerebrovascular disease registry and neurology clinic will be recruited. all participants will undergo octa retinal scan, mri-bold brain scan, cognitive battery evaluation, and blood sample at baseline and a 12-month follow-up visit. key outcome measures are: rvr, cvr, cognition, wmh volume, and cmb volume. the 40 patients diagnosed in the course of routine clinical care with swmd will be randomized in 1:1 ratio to receive cilostazol 100mg bid (or 50 mg bid if taking medications known to affect metabolism of cilostazol) or no cilostazol, and followed for wmd progression, and secondarily for changes in cognition, rvr and cvr. flow diagram below outlines the study design. note that in addition to what is shown in the trial flow diagram, patients will have telephone visits between baseline and 12 month clinic visits biweekly for 3 months and then monthly thereafter. these visits will consist of a survey for adverse events and at the 1-, 3-, 6- and 9-month telephone visits patients will also get a modified rankin scale assessment, a six-item screener (cognitive assessment) and a phq-2 (depression screen).

Eligibility criteria:
inclusion criteria: * age ≥18 yo. * diagnosis of cadasil, sporadic wmd or lobar cmb and age-matched healthy controls (eg. patient's spouse or unrelated friends without svd) exclusion criteria: * age\<18yo * pregnant * breast feeding * unable to follow commands * unable to tolerate mri
risk stratification for abdominal emergency surgery: a cohort study

Conditions: Emergency Surgery

Summary: the goal of this retrospective observational study is to identify risk factors of unwanted outcomes (in-hospital morbidity and mortality) among patients undergoing emergency abdominal surgery.

patients undergoing emergency abdominal surgery at a single tertiary care institution with a high volume of emergency abdominal surgeries, especially for high-acuity patients, between january 1, 2023, and june 1, 2024, will be included. baseline demographics, indication for surgery, and preoperative status (respiratory support, cardiovascular stability, glasgow score, sofa score, preoperative lab results, and preoperative waiting time including time to theatre (ttt) and time to knife (ttk)) will be recorded. definitions: time to theatre (ttt): the duration from when it is determined that the patient needs surgery to the time the patient arrives at the operating theatre. time to knife (ttk): the duration from when the patient enters the operating theatre to the time the first incision is made. these data will be retrieved from the electronic health record system. intraoperative factors, including asa classification, anesthesia method, type of surgical intervention, intraoperative lab results, transfusions, input/output (i/o), inotropic/vasopressor usage, and discharge ward, will also be retrieved from the electronic health record system. postoperative outcomes, including in-hospital mortality and morbidity (complications stratified by the clavien-dindo classification system), will be assessed by trained investigators. secondary outcomes include postoperative length of hospital stay and health care costs. a statistical model will be built to identify risk factors for morbidity and mortality.

Eligibility criteria:
inclusion criteria: patients undergoing emergency abdominal surgery at a single tertiary care institution between january 1, 2023, and june 1, 2024 exclusion criteria: repeated surgery for the same patients
comparison of turkish children's actual weights with which predicted weights by estimation methods

Conditions: Pediatric Hernia

Summary: the goal of this observational study is to compare body weigth with the prediceted weigth values abtracted by weigth estimation methods in turkish children. the main question it aims to answer is: to evaluate the suitability of apls, luscombe \& owens, best guess, nelson formula and broselow band methods in estimating actual measurements in patients coming to the surgery outpatient clinic of our hospital


Eligibility criteria:
inclusion criteria:admitted to the pediatric surgery clinic 0-18 years old patients will be included exclusion criteria:those who have a disease that will cause severe developmental growth retardation will be excluded
effectiveness of a diabetes education program based on tailored interventions (edep-ti study)

Conditions: Diabetes Mellitus, Type 2

Summary: goals: primary: 1. analyze the overall impact of the proposed diabetes education program on metabolic control (hba1c) and modifiable cardiovascular risk factors (lipid profile and blood pressure). secondary: 2. evaluate the effectiveness of the program on smoking habits and body mass index (weight, height). 3. analyze the impact of the program on the quality of life related to health. 4. check the effect on lifestyles: compliance levels of physical exercise and adherence to diet mediterranean. design: cluster randomized controlled trial

the reference population will be patients with a diagnosis of diabetes mellitus in treatment with oral antidiabetics, excluding the insulinized patients. they will then be randomly assigned by cluster, to the intervention group (individual education) or control (usual care) in the context of each health center participating in the project. after randomization centers, all professionals who decide to cooperate receive a training process on methodology for measuring results (clinical and questionnaire variables), while assigned to the experimental intervention, will also receive training on how to carry out the program of diabetologic education proposed. the follow-up period for both groups is 18 months obtained as clinical determinations: glycosylated hemoglobin (metabolic control), blood pressure, lipid profile, smoking and bmi; and as results reported by the patient through questionnaires: quality of life related to health, level of physical activity performed or adherence to the mediterranean diet.

Eligibility criteria:
inclusion criteria: * patients with type ii diabetes mellitus diagnosed \<10 years and classified in a computerized clinical history with poor metabolic control and in treatment with oral antidiabetics. * hba1c\> 7% in the last control available (\ 140 mmhg or dbp\> 90 mmhg, or presence of tobacco habit or dyslipidemia (ldl-c \> = 100 mg / dl) or bmi\> 30; or in treatment with: ace inhibitors, angiotensin ii receptor antagonists, beta-blockers, calcium channel blockers or diuretics and lipid-lowering drugs. exclusion criteria: * diabetes mellitus type 1 * insulinized patients. * patients who have received some type of structured educational intervention in the last year according to the data obtained in their clinical history. * patients with some type of sensory or mental disability. * gestational diabetes. * patients with age equal to or greater than 75 years of age or minors. * patients with inability to travel to their health center.

Keywords: patient education self-care controlled trial
pilot study to identify the influence of genetic profile aberrations on patients with recurrent hernias

Conditions: Pathological Processes

Summary: the aim of this study is to compare collagen composition in the skin and fascia of patients with recurrent or incisional hernias versus normal controls. we will identify potential genes responsible for genetic alterations in collagen deposition by using gene chip analysis of the tissue obtained and comparing the hernia group versus controls. the ultimate goal of this study is to identify target genes which may help us eventually predict which patients are at risk for developing post-operative hernias.

this is a prospective, case control pilot study with the aim of identifying potential genetic influences on recurrent hernia formation. patients with recurrent abdominal hernias will be compared with normal control subjects. the study endpoints will compare tissue collagen i/iii ratios between the groups. it will also use gene chip technology to identify potential differences in gene expression between the two groups, followed by confirmation of the differential expression using rt-pcr. patients will be enrolled from the surgical clinic population. if they consent to the study, both the hernia group and the control group will have 0.5 x 0.5 x 0.1 cm3 pieces of skin and fascia collected at the time of their surgery. a small piece of tissue will be used for immunofluorescene to study collagen i/iii ratios. rna will be extracted from the rest of the tissue for the genetic studies.

Eligibility criteria:
inclusion criteria: * hernia group: diagnosis of ventral or incisional hernia. * control group: appendicitis, symptomatic cholelithiasis or cholecystitis, adrenal disease necessitating adrenalectomy. * scheduled for an appropriate laparoscopic repair of above diagnosis. * females only: not pregnant. exclusion criteria: * steroid use * severe copd or pulmonary disorders * history of a connective tissue disorder * presentation for surgery with a diagnosis other than those listed above in inclusion criteria

Keywords: genomics
randomized controlled trial of milk products and physical activity on body composition and health in overweight young males

Conditions: Overweight

Summary: maintaining a healthy body weight is a major challenge for the majority of canadians. a lifestyle strategy that promotes maintenance of a healthy body weight and, perhaps most importantly, can be incorporated into daily life with relative ease is essential. this study will determine if an effective strategy includes increased physical activity in conjunction with higher intakes of dairy products immediately following exercise. fifty-six overweight adult males who do not regularly exercise will be assigned to one of four groups for 12 weeks. all groups will preform 12 weeks of exercise training (1 hour of cycling per day, 5 times per week). two groups will consume supplemental low fat milk (3 servings per day) with one these groups consuming it immediately after exercise while the other will consume it either well before or long after the exercise session. the other two groups will consume a carbohydrate drink that has the same amount of energy as the low fat milk, with one of these groups consuming the drink right after exercise and the other another group will consume it either well before or long after the exercise session. markers of health status including body weight, muscle mass, and bone mass will be measured at the start and after the 12- week intervention. the investigators anticipate that providing the low fat milk immediately after exercise will result in the most favorable changes in health outcomes, and provide a realistic lifestyle intervention for overweight individuals to attain a healthy body weight, and by doing so, optimize their ability to prevent chronic disease.


Eligibility criteria:
inclusion criteria: * bmi greater or equal to 25 * healthy exclusion criteria: * any chronic cardiovascular condition or metabolic condition * kidney disease * gastro-intestinal disease * milk or dairy protein allergies * lactose intolerance * chronic lung conditions * any condition that could potentially prevent participant from performing exercise * allergy to local anaesthetics * cumulative x-ray exposure and cumulative muscle biopsies
workwell: work-based activity and metabolic health

Conditions: PreDiabetes; Obesity

Summary: this study will test whether a range of pre-clinical cardiometabolic biomarkers can be improved via regular intervals of standing and light-intensity physical activity in real-world office environments.

this pilot study is being conducted to determine whether a range of pre-clinical cardiometabolic biomarkers (measured via gut microbiome, blood draw) can be improved via regular intervals of standing and light-intensity physical activity (i.e., leisurely walking) in real-world office environments. this trial is meant to generate pilot data which will lead to additional clinical trials. primary hypothesis: increasing both standing and light-intensity physical activity will improve biomarkers of metabolic function, as measured by blood metabolites and differential abundance of gut microbiome composition, compared to a control condition of normal workplace behavior.

Eligibility criteria:
inclusion criteria: * women and men age 18 yrs and older * holds a job where primary work activities are done seated * has the space and ability to use a sit-to-stand workstation in their primary workspace * works in an office setting or remotely for ≥ 4 days per week * have a bmi ≥ 25.0 (≥23.0 for individuals of asian descent) exclusion criteria: * currently taking diabetes medication * taking any of the following medications or treatments: * medication to control high blood pressure * medication to treat high glucose * blood thinners * hormone replacement therapy (in the past 12 months) * corticosteroids * high dose statins (dr. reaven, md to adjudicate eligibility based on dosage) * 2nd generation antipsychotics * current or previous foot or lower limb injuries * current use of sit-stand workstation * current smoker * neuromuscular or cardiovascular disorders or other serious active medical issues, including deep vein thrombosis or respiratory issues * has a physical impairment or musculoskeletal condition that will prevent the subject from standing or light-intensity walking for a maximum of 30 minutes * has been advised to avoid prolonged periods of sitting or standing by a physician or other healthcare provider * history of inflammatory bowel or intestinal malabsorption conditions * use of prebiotics, probiotics or antibiotics in the last 3 months * serious food allergies or restrictions * participants who will be travelling 3 or more days out of their typical week

Keywords: sedentary prediabetes lifestyle modification cardiometabolic health
study to evaluate efficacy and safety of bgb-3111 in participants with relapsed or refractory mantle cell lymphoma (mcl)

Conditions: Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma

Summary: the primary objective of this study was to evaluate the efficacy of zanubrutinib in participants with centrally confirmed relapsed or refractory mcl.


Eligibility criteria:
key inclusion criteria: 1. diagnostic report had to include evidence for morphological and cyclin d1 or t (11; 14). 2. eastern cooperative oncology group performance status of 0-2. 3. measurable disease by computed tomography/magnetic resonance imaging. 4. received prior regimens for mcl. 5. documented failure to achieve any response, (stable disease or progressive disease during treatment) or documented progressive disease after response to the most recent treatment regimen. 6. aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x upper limit of normal (uln). 7. total bilirubin ≤ 2 x uln (unless documented gilbert's syndrome). 8. life expectancy of \> 4 months. key exclusion criteria: 1. current or history of central nervous system lymphoma. 2. prior exposure to a btk inhibitor before enrollment. 3. prior corticosteroids with anti-neoplastic intent within 7 days. 4. major surgery within 4 weeks of screening. 5. toxicity must have recovered from prior chemotherapy. 6. history of other active malignancies within 2 years of study entry. 7. currently clinically significant active cardiovascular disease. 8. qt interval corrected with fridericia's formula \> 450 microseconds or other significant electrocardiogram abnormalities. 9. uncontrolled systemic infection or infection requiring parenteral anti-microbial therapy. 10. known human immunodeficiency virus infection, or active hepatitis b or hepatitis c infection (detected positive by polymerase chain reaction). note: other protocol-defined inclusion/exclusion criteria may apply.
efficacy of matrifen in patients older than 18 years with severe, chronic pain

Conditions: Severe, Chronic Pain

Summary: the aim of the study is to evaluate the efficacy and safety of matrifen in patients with severe and chronic pain who can only be sufficiently treated with opioid analgesics (who class 3).


Eligibility criteria:
main inclusion criteria: * patients with severe, chronic pain main exclusion criteria: * hypersensitivity of fentanyl * co-administration of monoaminooxidase-inhibitors * pregnancy * respiratory depression * chronic obstructive pulmonary disease (copd) * drug abuse * impairment of cns functions * other criteria as defined in the summary of product characteristics (fachinformation chapter 4.3)

Keywords: pain fentanyl transdermal patch
significance of cortactin expression in colorectal adenocarcinomas

Conditions: Cancer Colon

Summary: colorectal carcinoma is one of the most aggressive malignant epithelial neoplasms affecting the gastrointestinal tract. the incidence of colorectal carcinoma is obviously increasing in developing countries, where the physical inactivity and the consumption of animal fat-rich food became more evident. colorectal tumorigenesis is a multistep process which is initiated by adenoma and is terminated by carcinoma, the latter shows variable degrees of tumor differentiation and invasiveness. during the adenoma-carcinoma process; a series of genetic mutations occur. detection of these genetic mutations will help in the development of novel therapeutic agents, which in turn will improve patients' outcomes. cortactin (cttn) is a src kinase substrate, encoded by a gene located on chromosome 11. cttn binds to and activates arp 2/3 and stabilizes the dynamic actin assembly after its formation. so, it become clear that cttn is involved in the formation of the leading-edges cellular protrusions.

colorectal carcinoma is a highly lethal malignant epithelial tumor involving humans. the incidence of colorectal carcinoma is steadily increasing in developing countries, this could be assigned to low physical activity together with high consumption of animal fat-rich food. malignancy of the colon is a multistep process which is initiated by adenoma that proceeds to carcinoma, the latter includes a wide variety of tumor phenotypes. during the adenoma-carcinoma process; a series of genetic and epigenetic alterations occur. detection of these genetic alterations is of great benefit in the future management of colorectal carcinomas. cortactin (cttn) is a src kinase substrate, encoded by a gene located on chromosome 11. cttn anchors the dynamic actin assembly . cttn is implicated in the formation of the leading-edges cellular protrusions.the aim of this study is to evaluate expression of cttn in 50 cases of colorectal adenocarcinomas and their adjacent normal colonic mucosae.

Eligibility criteria:
inclusion criteria: * patients with colorectal carcinomas who underwent colectomy operations. exclusion criteria: * specimens obtained by lower endoscopy only, patients who received pre-operative chemotherapy.

Keywords: cancer colon cortactin immnuohistochemistry
telehealth autism assessment for adults

Conditions: Autism Spectrum Disorder

Summary: the study aims to investigate the reliability and validity of an adapted autism spectrum disorder assessment measure for use in a telehealth visit.


Eligibility criteria:
inclusion criteria: * age 18-60 years old * access to personal computer with video, microphone, and speaker * english literate * fluent english speaker exclusion criteria: * non-fluent english speaker * not english literate